Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis

Hua, Vivian; Kuo, Karen Y.; Cho, Hyunje Grace; Sarin, Kavita Y.

doi:10.1016/j.jaad.2019.08.046

Cited by 10 publications

(21 citation statements)

References 5 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a large cross-sectional study of adolescents in Israel, a gradual increase was seen in the prevalence of hyperhidrosis, from underweight to obese, in both male (1.5-2.9%) and female (1.1-1.6%) participants [44]. The current study supports the association between hyperhidrosis and HS [18]. If increased eccrine sweating occurs in HS individuals in general, the idea of using BTX-B is even more logical.…”

Section: Discussionsupporting

confidence: 73%

“…However, an impact on the QoL of patients with lesions of concurrent HS and hyperhidrosis activity was observed in a majority of the patients. The authors interestingly attribute the improvement, in part, to the positive effect on hyperhidrosis [18].…”

Section: Discussionmentioning

confidence: 95%

“…Five patients have previously received BTX-A injections for HS, with a positive outcome [14][15][16][17], whereas a study performed in five HS patients reported improvement in the Dermatology Life Quality Index (DLQI), but not for the number of nodules or VAS for pain [18].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

2020

View full text Add to dashboard Cite

Background Botulinum toxin (BTX) is a potent neurotoxin with a long history of therapeutic application in neurological and dermatological conditions, with a strong efficacy and safety profile. Objective Our aim was to assess whether intradermal injection with BTX-B is an effective treatment for hidradenitis suppurativa (HS). Methods Twenty patients with HS stage I-III disease, according to Hurley's classification, were consecutively included for treatment with either a placebo or BTX-B. At the next intervention after 3 months, all participants received the active substance and another follow-up at 6 months. The primary outcome was quality of life, measured using the Dermatology Life Quality Index (DLQI), while secondary outcomes were the visual analogue scale (VAS) for pain in the worst boil and HS-related impairment of general health (VAS), as well as changes in physician-reported disease activity assessed as the number of total lesions, and reported adverse effects of treatment. Results The DLQI improved from a median of 17 at baseline to 8 at 3 months in the BTX-B group, compared with a reduction from 13.5 to 11 in the placebo group (p <0.05). Improvement of the patients' own ratings of symptoms and a reduction in total lesions supplemented the primary outcome. Fifty-five percent of the study population reported some degree of hyperhidrosis. Conclusion BTX-B improves the quality of life in patients with HS. Furthermore, comorbidity between HS and hyperhidrosis is suggested. Trial Registration ClinicalTrials.gov identifier: NCT03103074.

show abstract

Section: Discussionsupporting

confidence: 73%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

2020

View full text Add to dashboard Cite

show abstract

“…2,3 An age-and gender-adjusted analysis of crosssectional data found a 3.61-fold increase in risk of hyperhidrosis in HS compared to control . 1 Currently, the mainstays of hyperhidrosis treatments include topical antiperspirants, systemic anticholinergics, BTX, and iontophoresis. Other modalities include local surgery, radiofrequency, microwave energy devices, and lasers.…”

Section: Discussionmentioning

confidence: 99%

Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review

Shih

Lee

Seivright

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients. In May 2021, MEDLINE and EMBASE databases were systematically searched by two reviewers per PRISMA guidelines for articles on hyperhidrosis and HS. Sixteen articles met inclusion criteria (2 randomized controlled trials [RCTs], one case-control study, three cross-sectional studies, 10 case-studies/ series), encompassing 252 HS patients across studies. They examined botulinum toxin A (BTX-A) (n = 6) and B (BTX-B) (n = 1), suction-curettage (n = 1), diode laser (n = 1), and microwave-based energy device (MED) (n = 3). Overall, BTX treatments improve HS severity, QOL, hyperhidrosis, and were well-tolerated. Suction-curettage did not improve disease. One HS patient tolerated diode laser well, with improvement in sweating and HS. One RCT studying MED was discontinued due to adverse events. Two studies reported MED-induced HS. BTX was overall helpful in HS patients, including in patients without concomitant hyperhidrosis. However, more prospective studies are needed to examine its utility in HS. There is potential harm of MEDs in HS. Most studies examining hyperhidrosis treatments in HS patients are low level of evidence. Larger RCTs should examine the efficacy and tolerability of hyperhidrosis treatments in HS.

show abstract

“…It affects apocrine regions with bullae, sinus tracts, fistulas, and cicatrices. HS patients have severe psychosocial distress and costs [148,149]. Even if HS may not be primarily a disease affecting the apocrine glands, the glands remain a potential therapeutic target [150].…”

Section: Hidradenitis Suppurativamentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis

Cited by 10 publications

References 5 publications

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study

Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Contact Info

Product

Resources

About